Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review.

Brittany SalterIan BurnsKatherine FullerAli EshaghpourAnath C LionelMark Crowther

Published in: European journal of haematology (2022)

The overall number of articles commenting on TLS as an adverse event is sparse and there needs to be more transparency regarding the incidence of TLS when employing newer targeted therapies. Physicians should consider the risk of TLS on an individual basis and the added risk of TLS when using TKIs to treat hematologic malignancy.

Keyphrases

primary care
risk factors
emergency department
neural network
drug induced